1Waldenstrom J. Incipient myelomatosis or essential hyperglobulinemia with fibrinogenopenia: a new syndrome? [J]. Acta Med Scand,1944,117(3/4):216-247.
2Treon SP, Morel P, Leblond V, et al. Report of the Third International Workshop on Waldenstrom's maeroglobulinemia[J].Clin Lymphoma,2005,5(4) :215-216.
3Vijay A, Oertz MA. Waldenstrom macroglobulinemia [J]. Blood,2007,109(12) :5096-5103.
4Schop RF,van Wier SA, Xu R, et al. 6q deletion discriminates WaldenstrOm macroglobulinemia from IgM monoclonal gammopathy of undetermined significance[J]. Cancer Genet Cytogenet, 2006,169(2) : 150 -153.
5Oeio EM, Schop RF, Gonzalez B, et al. 6q deletion in Waldenstrom maeroglobulinemia is associated with features of adverse prognosis[J]. Br J Haematol,2007,136(1) :80-86.
7Treon SP, Gertz MA, Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia [J]. Blood, 2006,107(9) :3442-3446.
8Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oneology Group S9003)[J]. Blood,2001,98(1) :41-48.
9Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in FcgmraaRIlIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia[J]. J Clin Oneol, 2005,23 ( 3 ) : 474-481.
10Ghobrial IM, Fonseca R, Greipp PR, et al. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom maeroglobulinemia: an Eastern Cooperative Oneology Group Study[J].Cancer, 2004,101 ( 11 ) : 2593-2598.
